A BIOMARKER AND PHASE II STUDY OF GW 572016 IN RECURRENT MALIGNANT GLIOMA (NA

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 具体目标 主要目标： ？确定使用GW572016治疗的复发或进展性胶质母细胞瘤患者的6个月无进展生存率。 ？确定GW572016是否抑制其细胞靶标EGFR和HER2的磷酸化，以及体内胶质母细胞瘤患者PI3K-AKT和RAS-ERK信号通路的下游。 ？确定GW572016的肿瘤浓度。 次要目标： ？总体无进展生存。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. SPECIFIC AIMS Primary aims: ¿ Determine the 6-month progression-free survival rate for patients with recurrent or progressive glioblastoma treated with GW572016. ¿ Determine whether GW572016 inhibits the phosphorylation of its cellular targets EGFR and HER2, and the downstream PI3K-AKT and RAS-ERK signaling pathways in glioblastoma patients in vivo. ¿ Determine tumor concentrations of GW572016. Secondary aims: ¿ Overall progression free survival.